Fucosyltransferase 8-defective CHO cell line as well as preparation method and application thereof
By designing and introducing sgRNA sequences in CHO cells to knock out the FUT8 gene, the gene editing efficiency is improved using CRISPR/Cas9 technology, solving the problem of low knockout efficiency of FUT8 gene in CHO cells, and significantly improving the ADCC activity of the antibody.
Patent Information
- Application Number
- CN202310561680.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-22
AI Technical Summary
The existing gene editing technology has low FUT8 knockout efficiency in CHO cells, resulting in difficulty in improving the ADCC activity of the antibody.
Design the sgRNA sequence that guides cleavage of nuclease and connects it to the CRISPR/Cas9 plasmid. The successfully constructed sgRNA plasmid was transfected into CHO cells by electrotransferring, and monoclonal cells were screened to obtain fucosyltransferase 8 defective CHO cells. Tie.
The ADCC activity of monoclonal antibodies was significantly improved, and experimental verification was achieved with high efficiency of FUT8 knockout efficiency and stable fucosyltransferase 8-deficient cell lines.
Smart Images

Figure CN118995622A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biotechnology, and more specifically, to a fucosyltransferase 8-deficient CHO cell line and a preparation method and application thereof. Background Art
[0002] Chinese hamster ovary (CHO) cells are an epithelial cell line derived from the ovary of the Chinese hamster and are one of the main tools for producing monoclonal antibodies. In CHO cells, α-(1,6)-fucosyltransferase (FUT8) can add fucosyl to asparagine 297 in the Fc region of the antibody, which can hinder the binding of the antibody Fc to the lymphocyte receptor, thereby reducing the antibody-dependent cell-mediated cytotoxicity (ADCC) activity. ADCC is mediated by the binding of the antibody Fc region to the lymphocyte receptor. Knocking out the FUT8 gene in CHO cells will completely eliminate the fucose at the Fc end of the antibody, thereby increasing the ADCC activity of the monoclonal antibody drug. At present, many studies have reported the effect of enhancing ADCC by disrupting the FUT8 gene through different methods, such as homologous recombination or zinc finger nucleases (ZFNs), which all increase ADCC activity.
[0003] Transcription activator like effector nuclease (TALEN) technology and zinc finger nuclease (ZFN) technology are a powerful class of genome editing tools. These two chimeric nucleases consist of two parts: an encodable sequence-specific DNA binding module and a non-specific DNA cleavage domain. TALEN and ZFN can knock out the FUT8 gene by inducing DNA double-strand breaks to stimulate error-prone non-homologous end joining or homology-directed repair at the location of specific genes.
[0004] The CRISPR / Cas9 system, which originated from the microbial adaptive immune system, is an efficient genome editing tool used in a variety of species including plants, animals, bacteria and yeast. This system only requires Cas9 and a single guide RNA (sgRNA) to achieve FUT8 gene knockout, and has the advantages of easy customization, higher targeting efficiency and the ability to facilitate multi-genome editing.
[0005] However, for the ZFN method, it is difficult to target non-G-rich positions for gene editing, and a large amount of protein engineering is required to construct the expression system; for the TALEN method, the 5' target base of each TALEN monomer must be T, and a complex molecular cloning method is required to construct the expression system. For the CRISPR / Cas9 method, the gene editing target position must be before the PAM sequence, and the positions in the gene that can be used as the targeting region to achieve positive knockout are limited. Since each method has certain constraints, the gene knockout efficiency of different methods is low. Therefore, how to improve the gene knockout efficiency of CHO cells is a difficulty in improving the ADCC activity of antibodies. Summary of the invention
[0006] In order to improve the gene knockout efficiency of CHO cells and further enhance the ADCC activity of antibodies, the present application provides a fucosyltransferase 8-deficient CHO cell line and a preparation method thereof.
[0007] This application adopts the following technical solutions: In a first aspect, the present application provides a method for preparing a fucosyltransferase 8-deficient CHO cell line, which comprises: designing a sgRNA sequence for guiding nuclease cleavage according to the sequence of the FUT8 gene, wherein the sgRNA sequence is as shown in SEQ ID NO.1, specifically: AAAATTACAAGAAACAAGCT (SEQ ID NO.1).
[0008] The sgRNA sequence was connected to the CRISPR / Cas9 plasmid after restriction digestion to obtain a connection vector, which was then transferred into bacterial competent cells. After sequencing and identification, a successfully constructed sgRNA plasmid was obtained; The sgRNA plasmid was then transfected into CHO cells, and single clone cells were screened for expanded culture to obtain a stable fucosyltransferase 8-deficient CHO cell line.
[0009] Furthermore, the above-mentioned CRISPR / Cas9 plasmid includes pSpCas9(BB)-2A-Puro(PX459).
[0010] Furthermore, the method for preparing the connection vector comprises: The sgRNA sequence is synthesized, and then annealed to generate double-stranded DNA oligo fragments. The sequences of the double-stranded DNA oligo fragments are shown in SEQ ID NO.2 and SEQ ID NO.3; Specifically, the sequence is: SEQ ID NO.2: CACCGAAAATTACAAGAAACAAGCT; SEQ ID NO. 3: AAACAGCTTGTTTCTTGTAATTTTC.
[0011] Digest the CRISPR / Cas9 plasmid with an endonuclease to obtain an enzyme-cut vector; The double-stranded DNA oligo fragment and the enzyme-cut vector are connected by ligase to obtain a connection vector.
[0012] Furthermore, the above-mentioned process of connecting the double-stranded DNA oligo fragment with the restriction-cut vector includes: Incubate the double-stranded DNA oligo fragment and the enzyme-cut vector in the ligation system at 20-30°C for 20-40 minutes.
[0013] Furthermore, the above-mentioned ligation system includes: 2-4 μL of restriction digestion vector, 0.5-1.5 μL of double-stranded DNA oligo fragment, 0.5-1.5 μL of T4 DNA ligase, and 1-2 μL of ligase buffer; The mass of the enzyme-cut vector is 40-60 ng, and the concentration of the double-stranded DNA oligo fragment is 0.3-0.7 μM.
[0014] Furthermore, in the above-mentioned process of preparing double-stranded DNA oligo fragments, the annealing procedure includes: Anneal at 90-100°C for 20-40s; Anneal at 70-75°C for 100-140s; Anneal at 35-40°C for 100-140s; Anneal at 23-28℃ for 100-140s.
[0015] Furthermore, the construction process of the above sgRNA plasmid includes: The ligated vector was transferred into bacterial competent cells, placed in LB medium containing 40-60 mg / L ampicillin, cultured at 35-40°C for 12-16 hours, and resistant transformants were isolated. After the plasmid was extracted, double enzyme digestion was performed for identification.
[0016] Furthermore, the above-mentioned transfection method for transfecting the sgRNA plasmid into CHO cells is electroporation, and the incubation temperature is 36-38°C and the time is 48-72h.
[0017] Furthermore, the above method for screening monoclonal cells after transfecting the sgRNA plasmid into CHO cells includes: 48-72 hours after transfection, cloning by limiting dilution method, culturing for 6-7 days, selecting monoclonal cells, and performing PCR sequencing verification to finally obtain a homozygous positive clone of fucosyltransferase 8-deficient CHO cell line.
[0018] In a second aspect, the present application also provides a fucosyltransferase 8-deficient CHO cell line prepared by the above preparation method.
[0019] In a third aspect, the present application also provides a method for expressing a target protein that is not fucosyl modified, comprising: introducing DNA encoding the target protein into the fucosyltransferase 8-deficient CHO cell line as described above to express the target protein.
[0020] In summary, this application has the following beneficial effects: The fucosyltransferase 8-deficient CHO cell line and preparation method provided in the present application are as follows: a sgRNA sequence for guiding nuclease cleavage is designed for the FUT8 gene, and the sgRNA sequence is linked to the CRISPR / Cas9 plasmid after enzyme cleavage, and then transferred into bacterial competent cells to obtain a successfully constructed sgRNA plasmid, and then the sgRNA plasmid is transfected into CHO cells, so that the nuclease is targeted to cut a specific sequence of the FUT8 gene under the guidance of the sgRNA, and finally a fucosyltransferase 8-deficient cell line of 3 homozygous positive clones is obtained.
[0021] The inventors verified through experiments that during the process of expressing monoclonal antibodies in the fucosyltransferase 8-deficient cell line, the ADCC activity of the monoclonal antibodies was significantly improved because the monoclonal antibodies produced by the cells no longer had α-1,6-fucosylation modification. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The electrophoresis detection results of the sgRNA vector prepared in Example 1 of the present invention; Figure 2 This is a schematic diagram of the structure of the sgRNA vector constructed in Example 1 of the present invention; Figure 3 This is a schematic diagram of the comparison results of the gene sequences near the knockout sites of the two homologous chromosomes #4 in Example 1 of the present invention and the Fut8 gene sequence; Figure 4 This is a schematic diagram of the comparison results of the gene sequences near the knockout sites of the two homologous chromosomes #17 in Example 1 of the present invention and the Fut8 gene sequence; Figure 5 This is a schematic diagram of the comparison results of the gene sequences near the knockout sites of the two homologous chromosomes #29 in Example 1 of the present invention and the Fut8 gene sequence; Figure 6 This is the ADCC assay verification result of the H_CD20 hIgG1 monoclonal antibody expressed by the fucosyltransferase 8-deficient cell line in the effect example of the present invention. DETAILED DESCRIPTION
[0023] The embodiments of the present invention will be described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. The specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0024] The technical solution of this embodiment is: A method for preparing a fucosyltransferase 8-deficient CHO cell line, comprising: Step S1: Design a sgRNA sequence for guiding nuclease cleavage according to the sequence of the FUT8 gene. The sgRNA sequence is shown in SEQ ID NO.1.
[0025] Specifically: AAAATTACAAGAAACAAGCT (SEQ ID NO. 1).
[0026] The sgRNA sequence with this specific sequence designed in the present application can effectively knock out the Fut8 gene, and obtain 3 homozygous positive clones of fucosyltransferase 8-deficient cell lines with high knockout efficiency.
[0027] Step S2: The sgRNA sequence is connected to the CRISPR / Cas9 plasmid after restriction digestion to obtain a connection vector, which is then transferred into bacterial competent cells. After sequencing and identification, a successfully constructed sgRNA plasmid is obtained.
[0028] Furthermore, the CRISPR / Cas9 plasmid includes pSpCas9(BB)-2A-Puro(PX459). This plasmid is a single-plasmid common vector, and the construction efficiency is higher when using the electroporation method. Compared with the viral plasmid construction, the experimental operation is simple.
[0029] Furthermore, the method for preparing the connection vector comprises: (1) synthesizing the sgRNA sequence, and then annealing and pairing to generate double-stranded DNA oligo fragments, the sequences of which are shown in SEQ ID NO. 2 and SEQ ID NO. 3; Specifically, the sequence is: SEQ ID NO.2: CACCGAAAATTACAAGAAACAAGCT; SEQ ID NO. 3: AAACAGCTTGTTTCTTGTAATTTTC.
[0030] Furthermore, in the above-mentioned process of preparing double-stranded DNA oligo fragments, the annealing procedure includes: Anneal at 90-100°C for 20-40s; Anneal at 70-75°C for 100-140s; Anneal at 35-40°C for 100-140s; Anneal at 23-28℃ for 100-140s.
[0031] (2) digesting the CRISPR / Cas9 plasmid with an endonuclease to obtain an enzyme-digested vector; (3) The double-stranded DNA oligo fragment is connected to the enzyme-cut vector by ligase to obtain a connected vector.
[0032] Preferably, the process of connecting the double-stranded DNA oligo fragment and the enzyme-cut vector comprises: incubating the double-stranded DNA oligo fragment and the enzyme-cut vector in the connection system at 20-30° C. for 20-40 minutes.
[0033] Preferably, the above-mentioned ligation system comprises: 2-4 μL of enzyme-cut vector, 0.5-1.5 μL of double-stranded DNA oligo fragment, 0.5-1.5 μL of T4 DNA ligase, and 1-2 μL of ligase buffer; The mass of the enzyme-cut vector is 40-60 ng, and the concentration of the double-stranded DNA oligo fragment is 0.3-0.7 μM.
[0034] Furthermore, the construction process of the above sgRNA plasmid includes: The ligated vector was transferred into bacterial competent cells, placed in LB medium containing 40-60 mg / L ampicillin, cultured at 35-40°C for 12-16 hours, and resistant transformants were isolated. After the plasmid was extracted, double enzyme digestion was performed for identification.
[0035] Step S3: The sgRNA plasmid is then transfected into CHO cells, and monoclonal cells are screened for expansion culture to obtain a stable fucosyltransferase 8-deficient CHO cell line.
[0036] Furthermore, the above-mentioned transfection method for transfecting the sgRNA plasmid into CHO cells is electroporation, and the incubation temperature is 36-38°C and the time is 48-72h.
[0037] Furthermore, the above method for screening monoclonal cells after transfecting the sgRNA plasmid into CHO cells includes: 48-72 hours after transfection, cloning by limiting dilution method, culturing for 6-7 days, selecting monoclonal cells, and performing PCR sequencing verification to finally obtain a homozygous positive clone of fucosyltransferase 8-deficient CHO cell line.
[0038] The specific embodiments of the present invention are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention. Example
[0039] Example 1 This embodiment provides a fucosyltransferase 8-deficient CHO cell line, and the preparation method thereof comprises: 1. sgRNA target design: In this example, sgRNA was creatively designed for the sequence of UT8 gene, and the sgRNA sequence is shown in SEQ ID NO.1: AAAATTACAAGAAACAAGCT.
[0040] 2. sgRNA and oligo single-stranded DNA were synthesized to obtain a pair of oligo sequences containing sticky ends with the same restriction site as the vector, named SEQ ID NO.2 and SEQ ID NO.3, the sequences are as follows: SEQ ID NO.2: CACCGAAAATTACAAGAAACAAGCT. SEQ ID NO.3:AAACAGCTTGTTTCTTGTAATTTTC. Dilute the primers with sterile TE buffer to a final concentration of 100 μM. Pipette 10 μl of the upstream and downstream primers, mix them, pipette evenly, and place them in a PCR tube for annealing. The procedure is as follows: After completion, place on ice for a few minutes and connect directly or store in a freezer at -20°C.
[0041] 3. Digest the vector pSpCas9(BB)-2A-Puro(PX459)V2.0 (source: addgene) at 37°C for about 30 minutes. Then perform gel recovery to obtain the linearized vector fragment. The enzyme digestion system is as follows: 4. Incubate the linearized vector fragment and the obtained annealing product in a 25°C water bath for 30 minutes to obtain a ligation product. The ligation system is as follows: 5. Transform the ligation product into competent cells stbl3, apply LB medium plates containing 50 mg / L ampicillin, and culture in a 37°C incubator for 12-16 hours. Single colonies will appear and ampicillin-resistant transformants can be isolated.
[0042] 6. Pick several single colonies for expansion and use Tiangen's endotoxin-free plasmid miniprep kit (catalog number: GK2007-20) for plasmid miniprep.
[0043] 7. Double enzyme digestion identification of the extracted plasmid (such as Figure 1 The insertion site, direction and sequence of the gene were verified to be completely correct by sequencing, and the plasmid with the correct sequencing was the constructed target plasmid, i.e., the sgRNA plasmid.
[0044] 8. Cell transfection: 8.1 Experimental equipment: Electroporator: Lonza AMAXA2b Electrophoresis instrument: Bio Rad 8.2 Cell culture conditions: Culture medium: F12K+10% FBS+1% P / S; Culture parameters: 37°C, 5% CO2, 95% air, 200 rpm.
[0045] 8.3 Cas9 and sgRNA single plasmid structure Figure 2 shown.
[0046] 8.4 Plasmid electroporation into target cells: 1) Prepare 100ul Nucleofector solution (82ul Nucleofector Solution + 18ul supplement solution) in Eppendorf tube and place at room temperature; 2) 6-well plate, 1 ml of complete medium, incubated in advance; 3) Count the cells, 2E6 cells are needed, centrifuge at 90xg for 10 min, remove the supernatant, and resuspend the cells in the Nucleofector solution prepared in the first step. Note that the cell resuspending time should not exceed 15 min, try to shorten the time; 4) Add 2 μg of sgRNA plasmid to the cell suspension in the previous step, and transfer the DNA suspension into the electroporation cup using a pipette tip. The sample must cover the bottom of the electroporation cup without bubbles, and then close the lid. 5) Select procedure U-027 according to the instructions; 6) Place the electric rotating cup into the designated slot, press the "X" button, and the program starts; 7) After the program is finished, take out the electric rotating cup; 8) Open the lid and immediately add 500ul of complete culture medium using a pipette. Use a special electroporation pipette to transfer about 600ul of the sample to a 6-well plate pre-incubated with 1ml of culture medium. Note that the cells after electroporation are very fragile, so avoid repeated blowing. Slightly mix the well plate, place it in the incubator, and observe the cell status regularly; 9) Obtaining monoclonal cells 72 hours after cell transfection, the dead cells were centrifuged out, the live cells were counted, and the cells were limitedly diluted and distributed to 5 96-well plates, 1 cell / well. After 6-7 days of cell culture, 30 monoclonal clones were selected and the remaining cells were frozen. The selected monoclonal cells were centrifuged to collect the precipitate, and PCR was performed using the one-step toyobo kit, and sequenced and verified using SEQ ID NO.4 and SEQ ID NO.5: SEQ ID NO.4: CACATTTTCCATCTCTGAACTACAGAA. SEQ ID NO.5: GCTCTTTAGCTCCATTTTCAATCC. Finally, three homozygous positive clones were obtained, which were fucosyltransferase 8-deficient CHO cell lines, named #4 (79 bp deletion), #17 (31 bp deletion), and #29 (8 bp deletion). Figure 3 , 4 and 5. Since the cell itself will carry out homologous recombination repair, different numbers of base deletions may occur.
[0047] Example 2 This embodiment provides a method for expressing a target protein (H_CD20 monoclonal antibody) without fucosyl modification, which comprises: 1. Design and synthesize the light and heavy chain primers of H_CD20 antibody plasmid, which are: F primer (SEQ ID NO.6): CTGCTGACCGGCGTGCGGGCC R primer (SEQ ID NO.7): GCTTGGGGCTGCCACGGTCCT R primer (SEQ ID NO.8): CGGAGGGTCCTTTGGTAGAAGC 2. Amplify the target fragment using PCR: The PCR system is as follows: The PCR program is as follows: 3. Double-digest the vector PCDNA3.4 with EcoRI and BamHI for 2h at 37°C, and then perform gel recovery to obtain the linearized vector fragment.
[0048] 4. Use Hieff CloneTM Plus One Step Cloning Kit (from Yeasen) to seamlessly clone and connect the linearized vector fragment and the two PCR products obtained.
[0049] The ligation reaction system was: 5×CE Buffer 4μl, vector 0.3ul, DNA fragment 0.2ul, seamless cloning enzyme 2ul, ddH2O 13.5ul, ligation at 50 degrees for 20min.
[0050] 5. Transform the ligated plasmid into competent cells stbl3, apply LB medium plates containing 50 mg / L ampicillin, and culture in a 37°C incubator for 12-16 hours. Single colonies will appear and ampicillin-resistant transformants can be isolated.
[0051] 6. Pick several single colonies for expansion and use Tiangen's endotoxin-free plasmid miniprep kit (catalog number: GK2007-20) for plasmid miniprep.
[0052] 7. Identification of successful plasmid construction: The extracted plasmid was subjected to double enzyme digestion identification, and sequencing verified that the insertion site, direction and sequence of the gene were completely correct. The plasmid with correct sequencing was the constructed target plasmid, i.e., the H_CD20 antibody plasmid.
[0053] 8. The constructed H_CD20 antibody plasmid was electroporated into the following two CHO cell lines: The first one is CHO-K1 cell line, which was purchased from ATCC and cultured in suspension and screened for monoclonal clones. The second one is CHO-K1#4 cell line, which is a fucosyltransferase 8-deficient cell line screened in Example 1 of the present invention, with a deletion of 79 bp, such as Figure 3 shown.
[0054] The electroporation steps are the same as in Example 1.
[0055] 9. Collect the supernatant culture fluid of each cell line 6 days after electroporation and purify it using Protein A affinity chromatography column. The specific purification steps are as follows: 1) Filler treatment: Take 400ul of filler into a centrifuge tube, wash 3 times with 5ml of ultrapure water each time, 4℃, 1200rpm, 3-5min; then wash 2-3 times with the same volume of PBS, and resuspend with 400ul of PBS after the last centrifugation; 2) Sample processing: The transfected cells were centrifuged at 3700 rpm, 4°C for 20 min and the supernatant was collected; 3) Capture: Add 800ul of treated filler to each cell supernatant, clamp the centrifuge tube to the flip mixer and incubate in a 4°C refrigerator for 2h. After incubation, centrifuge at 4°C, 1200rpm for 3-5min, and discard the supernatant; 4) After centrifugation, wash the bottom of the tube with 5 ml of Buffer A (PBS) three times, centrifuging at 1200 rpm for 3-5 minutes each time, and then remove the supernatant with a pipette; 5) Take 3.5 ml of Buffer B (acetic acid) for each sample, incubate for 10-20 minutes, and centrifuge at 1200 rpm for 3-5 minutes to obtain the supernatant; 6) Add Buffer D (Tris) to neutralize the eluate to a pH of 6.5-7.5, filter it with a 0.22 micron filter, and pour it into a 30KD concentrator tube for concentration; 7) Centrifuge at 3700 rpm, 4°C. The time is adjusted according to the volume after centrifugation. 8) Replace the sample with Buffer A: Add 5 ml of PBS to the concentrator tube each time, pipette gently to mix, continue concentrating, and repeat 3-4 times; 9) Mix the concentrated supernatant and transfer it into a 2.0mL screw-top conical EP tube.
[0056] 10. The Nanodrop concentration meter measures protein concentration, using the extinction coefficient or IgG method to obtain the concentration. The results are: The concentration of H_CD20 antibody prepared using CHO K1 cell line was 3.5 mg / ml; The concentration of H_CD20 antibody prepared using CHO K1#4 cell line was 2.9 mg / ml.
[0057] Effect example The ADCC effects of the two H_CD20 antibodies prepared in Example 2 were detected: 1. Antibody drug dilution: Use 1% FBS to dilute the two H_CD20 antibodies prepared in Example 2 in a 5-fold gradient, with the first well being 15ug / ml, 11+1 gradients, and 1 repeat; 2. Cell preparation: Plate cells 24 hours in advance. According to the drug dilution gradient, the number of plated wells should be at least 24; 3. Cell co-culture and antibody drug addition: Target cell H_CD20 Raji cell line clone (purchased from Jiman Biotechnology) was prepared into 1E6 cell / ml suspension, 50ul / well, and then 50ul 3E6 cell / ml ADCC FcγRIIIa (158V) Jurkat Effector Cell Line (purchased from Jiman Biotechnology) effector cells were added, and then 50ul of diluted H_CD20 antibody drug was added to each well; 4. After incubation for 7 hours, collect the cells, lyse the cells, and measure the luc value.
[0058] This experiment verifies the expression of the reporter gene by co-culturing target cells with effector cells and then adding diluted H_CD20 antibody drugs. In theory, the greater the fluorescence value of the reporter gene, the stronger the ADCC effect.
[0059] The results are as follows Figure 6 It shows that compared with the antibody produced by CHO-K1 cells purchased from ATCC, the antibody produced by the CHOK1#4 cell line monoclonal constructed in this patent has a higher fluorescence value, which indicates that the antibody expressed from the fucosyltransferase 8-deficient CHO cell line has improved ADCC activity.
[0060] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. A method for preparing a fucosyltransferase 8-deficient CHO cell line, It is characterized in that It includes: Design a sgRNA sequence for guiding nuclease cleavage according to the sequence of the FUT8 gene, wherein the sgRNA sequence is shown in SEQ ID NO.1; The sgRNA sequence is connected to the CRISPR / Cas9 plasmid after restriction digestion to obtain a connection vector, and the connection vector is transferred into bacterial competent cells. After sequencing and identification, a successfully constructed sgRNA plasmid is obtained; The sgRNA plasmid is then transfected into CHO cells, and monoclonal cells are screened out for expansion culture to obtain a stable fucosyltransferase 8-deficient CHO cell line.
2. The method for preparing a fucosyltransferase 8-deficient CHO cell line according to claim 1, It is characterized in that The CRISPR / Cas9 plasmid includes pSpCas9(BB)-2A-Puro (PX459).
3. The method for preparing a fucosyltransferase 8-deficient CHO cell line according to claim 1 or 2, It is characterized in that The method for preparing the connection carrier comprises: The sgRNA sequence is synthesized, and then annealed to produce double-stranded DNA oligo fragments, the sequences of the double-stranded DNA oligo fragments are shown in SEQ ID NO.2 and SEQ ID NO.3; Digest the CRISPR / Cas9 plasmid with an endonuclease to obtain an enzyme-digested vector; The double-stranded DNA oligo fragment and the enzyme-cut vector are connected by ligase to obtain the connection vector.
4. The method for preparing a fucosyltransferase 8-deficient CHO cell line according to claim 3, It is characterized in that The process of connecting the double-stranded DNA oligo fragment with the enzyme-cut vector comprises: The double-stranded DNA oligo fragment and the enzyme-cut vector are incubated in a ligation system at 20-30° C. for 20-40 minutes.
5. The method for preparing a fucosyltransferase 8-deficient CHO cell line according to claim 4, It is characterized in that The ligation system includes: 2-4 μL of enzyme-cut vector, 0.5-1.5 μL of double-stranded DNA oligo fragment, 0.5-1.5 μL of T4 DNA ligase, and 1-2 μL of ligase buffer; The mass of the enzyme-cut vector is 40-60 ng, and the concentration of the double-stranded DNA oligo fragment is 0.3-0.7 μM.
6. The method for preparing a fucosyltransferase 8-deficient CHO cell line according to claim 3, It is characterized in that The construction process of the sgRNA plasmid includes: The ligated vector is transferred into bacterial competent cells, placed in LB medium containing 40-60 mg / L ampicillin, cultured at 35-40° C. for 12-16 hours, and resistant transformants are separated. After the plasmid is extracted, double enzyme digestion is performed for identification.
7. The method for preparing a fucosyltransferase 8-deficient CHO cell line according to claim 1, It is characterized in that The transfection method for transfecting the sgRNA plasmid into CHO cells is electroporation, and the incubation temperature is 36-38° C. and the time is 48-72 hours.
8. The method for preparing a fucosyltransferase 8-deficient CHO cell line according to claim 1, It is characterized in that After transfecting the sgRNA plasmid into CHO cells, the method for screening the monoclonal cells comprises: 48-72 hours after transfection, the cells were cloned by limiting dilution method and cultured for 6-7 days. After the single clone cells were selected, PCR sequencing was performed for verification, and finally a homozygous positive clone of fucosyltransferase 8-deficient CHO cell line was obtained.
9. A fucosyltransferase 8-deficient CHO cell line prepared by the preparation method according to any one of claims 1 to 8.
10. A method for expressing a target protein without fucosyl modification, It is characterized in that It includes: The DNA encoding the target protein is introduced into the fucosyltransferase 8-deficient CHO cell line as claimed in claim 9 to express the target protein.
